Pear Therapeutics and Thimble Point Announce Closing of Business Combination to Create Publicly Traded Prescription Digital Therapeutics Company

News
2021
2020
Archive

December 6, 2021

Pear Therapeutics and Thimble Point Announce Closing of Business Combination to Create Publicly Traded Prescription Digital Therapeutics Company
December 3, 2021

CAMP4 Presents In Vivo Data Supporting Novel Therapeutic Strategy for Dravet Syndrome at American Epilepsy Society Annual Meeting
December 3, 2021

Rallybio Reports Positive Data in Its Clinical Program for the Prevention of Fetal and Neonatal Alloimmune Thrombocytopenia (FNAIT)
November 22, 2021

Pear Therapeutics Receives FDA Breakthrough Device Designation for Prescription Digital Therapeutics Candidate to Treat Alcohol Use Disorder
November 19, 2021

Arvinas and Pfizer Announce Updated Phase 1 Dose Escalation Data for ARV-471 to be Presented in Spotlight Poster Session at 2021 San Antonio Breast Cancer Symposium
November 17, 2021

Novome Biotechnologies Reports Positive Results from a Phase 1 Study of NOV-001
November 16, 2021

Thimble Point and Pear Therapeutics Announce Additional $50 Million in Committed Capital to Fund Business Plan
November 10, 2021

Crinetics Pharmaceuticals Presenting New Data From Open Label Extension Trial of Paltusotine in Acromegaly at the Society for Endocrinology BES Congress
November 10, 2021

Nouscom to Present Interim Data From Phase 1 Trial Evaluating NOUS-209, an “Off-The-Shelf” Neoantigen Cancer Vaccine for the Treatment of MSI-H Solid Tumors
November 10, 2021

Pear Therapeutics Announces Inclusion of reSET® and reSET-O® on the November 2021 MassHealth Drug List Summary Update and MassHealth Non-Drug Product List

1
2
3
…
15
Next Page »

© 2021 5AM Venture Management LLC